. . . . . "S&T TWOC Project - version 4" . "S&T TWOC version 3" . "2"^^ . "2023-07-20T09:47:21.594880"^^ . . . "antivirals like remdesivir , lopinavir , ritonavir , arbidol , oseltamivir , penciclovir , favipiravir , ganciclovir , and ribavirin ;" . "(60, 66)" . "including" . "67" . "different pharmacological groups" . "(60, 66)" . "Results Repurposing of drugs from different pharmacological groups including antivirals like remdesivir, lopinavir, ritonavir, arbidol, oseltamivir, penciclovir, favipiravir, ganciclovir, and ribavirin; other antibiotics like azithromycin, ivermectin, eravacycline, valrubicin, streptomycin, nitazoxanide, teicoplanin, caspofungin, and colistin; and other agents like hydroxychloroquine, chloroquine, tocilizumab, camostat, nafamostat, carfilzomib, interferon, aprepitant, and dexamethasone can be considered for COVID-19 therapy." . "8j41d0a3" . "8j41d0a3-TRIPLE-ABSTRACT-1" . "groups" . "antivirals" . "RSA" . "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" . "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" . . .